Novel biomarkers in preeclampsia.
Preeclampsia is a pregnancy-associated disease with maternal symptoms, but placental origin. Although clinical symptoms are late, systemic and maternal, the origin of preeclampsia is early, local and placental. Despite that various protein biomarkers display changed levels in maternal serum at presymptomatic stages, they lack discriminative and predictive power in individual patients. In contrast to protein markers, placental RNA analyzed in maternal plasma permits rapid screening of novel biomarkers including markers not accessible by antibody based assays. This includes transcription factors, non-coding RNA, epigenetic features, as well as genes functionally or genetically linked with preeclampsia. By reviewing genes with placental expression in the Human SymAtlas and comparison with proven qualifiers, a large set of RNA biomarkers was targeted for use in maternal plasma. These biomarkers qualify as novel RNA biomarkers for the presymptomatic detection in first trimester of pregnancy-associated diseases with placental origin and/or dysfunction such as pregnancy-induced hypertension without or with proteinuria (preeclampsia), the HELLP syndrome, and intrauterine growth restriction.
Smets
Eva M L
EM
Department of Clinical Chemistry, VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
Visser
Allerdien
A
Go
Attie T J I
AT
van Vugt
John M G
JM
Oudejans
Cees B M
CB
D015415:Biomarkers / Q000032:analysis / Q000097:blood*; D004247:DNA / Q000097:blood; D005260:Female; D006801:Humans; D010920:Placenta / Q000737:chemistry / Q000378:metabolism; D011225:Pre-Eclampsia / Q000097:blood / Q000175:diagnosis* / Q000235:genetics; D011247:Pregnancy; D012313:RNA / Q000097:blood
D015415:Biomarkers; D012313:RNA; D004247:DNA